Altimmune (NASDAQ:ALT) Releases Earnings Results

Altimmune (NASDAQ:ALT) announced its quarterly earnings results on Wednesday. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.25) by $0.07, FiscalAI reports. Altimmune had a negative net margin of 214,860.98% and a negative return on equity of 49.35%.

Here are the key takeaways from Altimmune’s conference call:

• Altimmune said it raised $225 million in an oversubscribed April offering, bringing pro forma cash to about $535 million and funding the company through the expected 2029 Phase III MASH 52-week data readout.
• The company said its global Phase III MASH study, PERFORMA, is on track to start in the second half of 2026, with the protocol finalized and aligned with both the FDA and EMA.
• Management emphasized pemvidutide’s potential differentiation in MASH, pointing to a favorable tolerability profile, simple titration, sustained weight loss, and possible preservation of lean muscle mass versus some competing GLP-1-based therapies.
• Altimmune said the 48-week Phase II IMPACT results will be presented orally at EASL, including additional fibrosis analysis and other biomarker data, which the company said should reinforce interest in the program.
• Beyond MASH, Altimmune remains on track to report Phase II AUD top-line data next quarter and expects to complete enrollment in the ALD RESTORE trial in the third quarter of 2026.

Altimmune Stock Performance

Shares of NASDAQ:ALT traded down $0.06 during mid-day trading on Wednesday, reaching $3.02. The company had a trading volume of 3,575,240 shares, compared to its average volume of 4,538,451. Altimmune has a one year low of $2.56 and a one year high of $7.73. The company has a current ratio of 18.55, a quick ratio of 18.55 and a debt-to-equity ratio of 0.15. The company’s 50-day moving average price is $3.34 and its 200-day moving average price is $4.12. The firm has a market cap of $392.90 million, a price-to-earnings ratio of -2.99 and a beta of 0.18.

Insiders Place Their Bets

In other Altimmune news, CEO Jerome Benedict Durso acquired 20,000 shares of the business’s stock in a transaction that occurred on Friday, March 6th. The stock was bought at an average cost of $3.54 per share, with a total value of $70,800.00. Following the acquisition, the chief executive officer owned 32,500 shares in the company, valued at approximately $115,050. This represents a 160.00% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 1.60% of the company’s stock.

Institutional Trading of Altimmune

A number of hedge funds and other institutional investors have recently made changes to their positions in ALT. Arax Advisory Partners boosted its stake in Altimmune by 99.7% in the 4th quarter. Arax Advisory Partners now owns 8,165 shares of the company’s stock worth $29,000 after purchasing an additional 4,076 shares during the period. Quadrature Capital Ltd bought a new stake in shares of Altimmune during the fourth quarter valued at about $36,000. CreativeOne Wealth LLC purchased a new stake in shares of Altimmune in the fourth quarter worth about $38,000. Victory Capital Management Inc. purchased a new stake in shares of Altimmune in the third quarter worth about $38,000. Finally, BNP Paribas Financial Markets boosted its position in shares of Altimmune by 108.5% in the second quarter. BNP Paribas Financial Markets now owns 10,095 shares of the company’s stock valued at $39,000 after acquiring an additional 5,253 shares during the period. 78.05% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the company. HC Wainwright raised their price objective on Altimmune from $12.00 to $25.00 and gave the company a “buy” rating in a report on Monday, March 16th. William Blair reiterated a “market perform” rating on shares of Altimmune in a research report on Thursday, March 5th. Barclays began coverage on Altimmune in a research note on Tuesday, January 27th. They set an “overweight” rating and a $20.00 price target on the stock. B. Riley Financial reduced their price target on Altimmune from $18.00 to $13.00 and set a “buy” rating on the stock in a report on Friday, March 6th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Altimmune in a report on Friday, March 27th. Seven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $18.00.

About Altimmune

Altimmune, Inc is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune’s approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.

Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose.